NCCN Updates Guidelines for clonoSEQ Testing Adoption and Medicare Coverage
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
The National Comprehensive Cancer Network updated its multiple myeloma guidelines on September 17. These recommendations specifically name clonoSEQ and expand testing time points to include annual assessments during maintenance and testing after later treatment lines. The preferred sensitivity for monitoring minimal residual disease is one cancer cell in one million cells, with a recommended minimum of one in 100,000.
From insidermonkey.com
Why it matters
The updates strengthen the clinical case for increased testing frequency across a patient’s treatment journey. The guidelines establish specific parameters for when and how clonoSEQ testing should be incorporated into routine clinical workflows.
From insidermonkey.com
Who's involved
- National Comprehensive Cancer NetworkNon-profit organization whose clinical guidelines are used to inform cancer treatment protocols in the USA.
- Guardant HealthBiotechnology company whose product was formally included in the NCCN colorectal cancer screening guidelines.
- Gilead SciencesAmerican company whose drug preferred status is influenced by NCCN reviews.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- MedicareSpeculative
The guidelines leverage existing Medicare coverage, which could increase the volume of actionable testing orders.